Otros idiomas Oncolys BioPharma Inc.

Acciones

4588

JP3202170001

Mercado cerrado - Japan Exchange Otros sitios de cotización 08:00:00 22/05/2024			Varia. Cinco días.	Varia. 1 de enero.
622 ^JPY	0,00 %		-9,33 %	+9,70 %

09/02	Oncolys BioPharma Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
07/02	Medigen Biotechnology Corp. anuncia la firma del acuerdo de cooperación para la venta del nuevo fármaco OBP-301 en Japón	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/02
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	07/02
Oncolys BioPharma : Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma	20/12
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine	20/12
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal Adenocarcinoma	07/11
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy	02/11
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	16/10/23
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	16/10/23
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin?? in Combination Therapy	10/08/23
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	04/08/23
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug	26/07/23
Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome	25/07/23
Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	24/07/23
Oncolys BioPharma Inc. announced that it expects to receive ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	07/07/23
ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma	06/06/23
Oncolys BioPharma Announces Results from an Investigator-Initiated Phase II Clinical Trial for Telomelysin™? (OBP-301) in Combination with Pembrolizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma	06/06/23
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023	12/05/23
Oncolys BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Amyotrophic Lateral Sclerosis	07/03/23
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2022	04/11/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Oncolys BioPharma Inc.

Acciones

4588

JP3202170001

Otros idiomas

Filtros